Gantenerumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gantenerumab?
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
  • Investigational
Identifiers
89957-37-9 N
None
UNII 4DF060P933 YesY
KEGG D09680 YesY
Chemical data
Formula C6496H10072N1740O2024S42
146.3 kDa (peptide)
 N (what is this?)  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. [4]

One clinical study was stopped on December 19, 2014 after disappointing results.[5]

As of late 2014, Phase III clinical trials are ongoing.[6]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. ^ Clinical trial number NCT00531804 for "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease" at ClinicalTrials.gov
  4. ^ http://www.scarletroadstudy.com/en-CA/index.aspx
  5. ^ http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045
  6. ^ H. Spreitzer (10 November 2014). "Neue Wirkstoffe – Gantenerumab". Österreichische Apothekerzeitung (in German) (23/2014): 55.